Jagsonpal Pharmaceuticals Limited Market Cap ($154.16 Million)
Market Cap & Net Worth: Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)
Jagsonpal Pharmaceuticals Limited market cap. Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) has a market capitalization of $154.16 Million (Rs14.25 Billion) as of November 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #17360 globally and #918 in its home market, demonstrating a -3.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jagsonpal Pharmaceuticals Limited's stock price Rs216.21 by its total outstanding shares 65929470 (65.93 Million). Also see Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) cash conversion ratio for how efficiently the company converts equity into cash flow.
Jagsonpal Pharmaceuticals Limited Market Cap History (2015–2026)
Jagsonpal Pharmaceuticals Limited market cap history from 2015 to 2026. Data shows growth from $31.98 Million to $154.16 Million (18.35% CAGR). Check latest Jagsonpal Pharmaceuticals Limited stock price today for real-time trading data and today's change.
Jagsonpal Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jagsonpal Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.05x
Jagsonpal Pharmaceuticals Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.36x
Jagsonpal Pharmaceuticals Limited's market cap is 0.36 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $25.08 Million | $1.44 Billion | $118.65 Million | 0.02x | 0.21x |
| 2018 | $20.67 Million | $1.27 Billion | -$115.51 Million | 0.02x | N/A |
| 2019 | $17.14 Million | $1.67 Billion | $72.16 Million | 0.01x | 0.24x |
| 2020 | $48.37 Million | $1.59 Billion | $78.71 Million | 0.03x | 0.61x |
| 2021 | $124.65 Million | $1.88 Billion | $170.58 Million | 0.07x | 0.73x |
| 2022 | $259.72 Million | $2.18 Billion | $188.55 Million | 0.12x | 1.38x |
| 2023 | $273.96 Million | $2.37 Billion | $267.21 Million | 0.12x | 1.03x |
| 2024 | $435.54 Million | $2.09 Billion | $224.63 Million | 0.21x | 1.94x |
| 2025 | $137.33 Million | $2.69 Billion | $553.61 Million | 0.05x | 0.25x |
| 2026 | $154.16 Million | $2.87 Billion | $430.82 Million | 0.05x | 0.36x |
Competitor Companies of JAGSNPHARM by Market Capitalization
Companies near Jagsonpal Pharmaceuticals Limited in the global market cap rankings as of November 4, 2026. Also see JAGSNPHARM current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Jagsonpal Pharmaceuticals Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Jagsonpal Pharmaceuticals Limited (2015–2026)
Market capitalization of Jagsonpal Pharmaceuticals Limited from 2015 to today. Between 2015 and today, Jagsonpal Pharmaceuticals Limited's market cap moved from $31.98 Million to $ 154.16 Million, with a yearly change of 18.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs154.16 Million | +12.25% |
| 2025 | Rs137.33 Million | -68.47% |
| 2024 | Rs435.54 Million | +58.98% |
| 2023 | Rs273.96 Million | +5.48% |
| 2022 | Rs259.72 Million | +108.36% |
| 2021 | Rs124.65 Million | +157.71% |
| 2020 | Rs48.37 Million | +182.15% |
| 2019 | Rs17.14 Million | -17.06% |
| 2018 | Rs20.67 Million | -17.58% |
| 2017 | Rs25.08 Million | +12.22% |
| 2016 | Rs22.35 Million | -30.11% |
| 2015 | Rs31.98 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Jagsonpal Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $154.16 Million USD |
| MoneyControl | $154.16 Million USD |
| MarketWatch | $154.16 Million USD |
| marketcap.company | $154.16 Million USD |
| Reuters | $154.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more